MNQ 0.00% 0.0¢ minquest limited

Ann: ePAT selected for CSIRO's ON Accelerator Program-MNQ.AX, page-44

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 980 Posts.
    lightbulb Created with Sketch. 320
    Clinical evidence for this app would be limited purely because it is not as black and white as a cough where the patient either has a sickness or not. Currently there is no standardised measurement to assess whether or not a patient is experiencing pain - and there cant be for these types of patients because they cannot communicate.

    The current Abbey pain scale is very subjective. From an article last year “We think it could be an absolute game changer and set the gold standard in that there should be an objective way in which to determine the presence of pain in people who have communication difficultly,” Prof Hughes

    Also from their website - There have been years of scientific research from world leaders in the assessment and detection of pain for ePat. They have clearly found common denominators in patients which experience pain, whether its facial cues, noises or movements.

    I think these are new roads being travelled on with ePat leading the way.
 
watchlist Created with Sketch. Add MNQ (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.